Editor's Note on 'Mutagenesis of human DNA polymerase λ: essential roles of Tyr505 and Phe506 for both DNA polymerase and terminal transferase activities'. [PDF]
europepmc +1 more source
Editor's Note on 'Mechanisms of transcriptional repression of cell-cycle G2/M promoters by p63'. [PDF]
europepmc +1 more source
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake +4 more
wiley +1 more source
Editor's Note: Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. [PDF]
europepmc +1 more source
This protocol paper outlines methods to establish the success of a time‐resolved serial crystallographic experiment, by means of statistical analysis of timepoint data in reciprocal space and models in real space. We show how to amplify the signal from excited states to visualise structural changes in successful experiments.
Jake Hill +4 more
wiley +1 more source
Editor's Note on 'A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response'. [PDF]
europepmc +1 more source
Comment on: Editor's Note on Clin-STAR Corner: Practice-Changing Advances in Diabetes Care. [PDF]
Kahkoska AR, Pratley RE.
europepmc +1 more source
Screening and epitope characterization of Nidogen‐2‐specific nanobodies
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen +9 more
wiley +1 more source
Editor's Note on 'A regulatory circuit comprising GATA1/2 switch and microRNA-27a/24 promotes erythropoiesis'. [PDF]
europepmc +1 more source
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel +8 more
wiley +1 more source

